NYSEARCA:XBISPDR S&P Biotech ETF Stock Price, Forecast & News

SPDR S&P Biotech ETF's stock was trading at $79.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XBI stock has increased by 45.5% and is now trading at $114.92. View which stocks have been most impacted by Coronavirus.

SPDR S&P Biotech ETF announced a quarterly dividend on Friday, December 20th. Investors of record on Monday, December 23rd will be given a dividend of $0.0009 per share on Thursday, December 26th. This represents a $0.00 dividend on an annualized basis and a yield of 0.00%. The ex-dividend date of this dividend is Friday, December 20th. View SPDR S&P Biotech ETF's dividend history.

Media headlines about XBI stock have trended somewhat positive recently, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SPDR S&P Biotech ETF earned a news impact score of 1.3 on InfoTrie's scale. They also assigned news coverage about the exchange traded fund a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about SPDR S&P Biotech ETF.

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include iShares Nasdaq Biotechnology ETF (IBB), NVIDIA (NVDA), Netflix (NFLX), Walt Disney (DIS), Intel (INTC), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Cisco Systems (CSCO) and Pfizer (PFE).

SPDR S&P Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI."

SPDR S&P Biotech ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Whittier Trust Co. (0.41%), Whittier Trust Co. of Nevada Inc. (0.15%), Carnegie Capital Asset Management LLC (0.15%), Courier Capital LLC (0.07%), Enterprise Bank & Trust Co (0.04%) and Envestnet Asset Management Inc. (0.04%).

XBI stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Courier Capital LLC, Wiley BROS. Aintree Capital LLC, and Wealth Alliance Advisory Group LLC.

XBI stock was purchased by a variety of institutional investors in the last quarter, including Legacy Private Trust Co., Ayalon Holdings Ltd., M&R Capital Management Inc., Whittier Trust Co. of Nevada Inc., Curbstone Financial Management Corp, N.E.W. Advisory Services LLC, Carroll Financial Associates Inc., and Clarus Wealth Advisors.

Shares of XBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XBI stock can currently be purchased for approximately $114.92.

SPDR S&P Biotech ETF has a market capitalization of $6.03 billion.

The official website for SPDR S&P Biotech ETF is www.spdrs.com.

SPDR S&P Biotech ETF's mailing address is One Lincoln Street, Boston, 02111, United States. The exchange traded fund can be reached via phone at +1-866-7872257.